特寶生物(688278.SH):2021年度淨利預增51.84%-56.99%
格隆匯1月28日丨特寶生物(688278.SH)公佈2021年年度業績預增公吿,經公司財務部門初步測算,預計2021年年度實現歸屬於母公司所有者的淨利潤為1.77億元到1.83億元,與上年同期(法定披露數據)相比,預計將增加6043.04萬元到6643.04萬元,同比增加51.84%到56.99%。
公司預計2021年年度實現歸屬於母公司所有者扣除非經常性損益後的淨利潤為1.92億元到2.02億元,與上年同期(法定披露數據)相比,預計將增加8126.25萬元到9126.25萬元,同比增加73.38%到82.41%。
業績變化的主要原因:報吿期內,公司積極應對市場變化,克服疫情影響,調整和優化經營計劃,派格賓等主營業務產品的銷售收入持續增加,淨利潤實現穩步增長;報吿期內公司收到政府補助較去年同期有所減少,公益捐贈較去年同期有所增加。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.